Non- effervescent Paracetamol kern — Competitive Intelligence Brief

Non- effervescent Paracetamol kern (Non- effervescent Paracetamol kern) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Analgesic and antipyretic. Area: Pain Management.

marketed Analgesic and antipyretic Cyclooxygenase (COX-1, COX-2) Pain Management Small molecule

Target snapshot

Non- effervescent Paracetamol kern (Non- effervescent Paracetamol kern) — Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina. Paracetamol inhibits prostaglandin synthesis by blocking cyclooxygenase enzymes in the central nervous system, reducing pain and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Non- effervescent Paracetamol kern TARGET	Non- effervescent Paracetamol kern	Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina	marketed	Analgesic and antipyretic	Cyclooxygenase (COX-1, COX-2)
Tylenol Pill	Tylenol Pill	Shanghai Zhongshan Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Acetaminophen/APAP	Acetaminophen/APAP	John van den Anker	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Postoperative pain management with acetaminophen	Postoperative pain management with acetaminophen	University Hospital Sestre Milosrdnice	marketed	Analgesic and antipyretic	Cyclooxygenase (COX), primarily central nervous system isoforms
Per Os Acetaminophen	Per Os Acetaminophen	Hospital for Special Surgery, New York	marketed	Non-opioid analgesic and antipyretic	Cyclooxygenase (COX), primarily in central nervous system
Acetaminophen Injectable Product	Acetaminophen Injectable Product	Rush University Medical Center	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes
Acetaminophen (Ofirmev)	Acetaminophen (Ofirmev)	Brigham and Women's Hospital	marketed	Analgesic and antipyretic	Cyclooxygenase (COX) enzymes (central nervous system)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Analgesic and antipyretic class)

1. Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina · 2 drugs in this class
2. Mallinckrodt · 2 drugs in this class
3. The University of Texas Health Science Center, Houston · 2 drugs in this class
4. Hellenic Society of Hematology · 1 drug in this class
5. John van den Anker · 1 drug in this class
6. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 drug in this class
7. Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 drug in this class
8. Merck Sharp & Dohme LLC · 1 drug in this class
9. Mount Sinai Hospital, Canada · 1 drug in this class
10. Nantes University Hospital · 1 drug in this class